Filter Articles
Rare Disease Day
At GBS|CIDP Foundation International, we recognize the power of unity and awareness in the fight…
Understanding CIDP and How Immunoglobulin Treatment Works
Educational Webinar Now On-Demand! “What Happens in CIDP and How Does Immunoglobulin Treatment Work?” is…
GBS|CIDP Foundation Hosts a Virtual Summit
Back by popular demand, our 2024 Virtual Summit, on Friday, September 27th and Saturday, September…
Hey doc, are you sure this is CIDP?
Hey doc, are you sure this is CIDP? By Jeffrey A. Allen MD,University of Minnesota…
A Clinical Study of Rozanolixizumab in Patients with CIDP
Clinical research studies are scientific evaluations in people, led by researchers and physicians. They can…
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy
Published in The Lancet, May 7, 2019Co-authored by Carina Bunschoten, Bart C Jacobs, Peter U…
CIDP Disease Burden — Results of a US Nationwide Patient Survey
In 2017, a nationwide survey of US CIDP patients was conducted to assess the impact…
Research in CIDP: Are we making progress?
By Jeffrey A. Allen, MDMember, GBS|CIDP Foundation Global Medical Advisory Board CIDP as a named…
Subcutaneous Immunoglobulin: A Newly Approved Treatment Option for CIDP
David Saperstein, MDCo-Director GBS/CIDP Center of ExcellencePhoenix Neurological AssociatesPhoenix, AZ Intravenous immunoglobulin (IVIg) is one…
FDA approves CSL Behring treatment for CIDP
The Food and Drug Administration granted marketing clearance Friday for Hizentra, a treatment for chronic inflammatory demyelinating…